Zacks Research Issues Negative Forecast for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for Sarepta Therapeutics in a research note issued on Monday, January 6th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $1.90 per share for the quarter, down from their prior forecast of $1.98. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.16 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.63 EPS, Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at $2.83 EPS, FY2025 earnings at $9.95 EPS, Q1 2026 earnings at $3.04 EPS, Q2 2026 earnings at $3.56 EPS, Q3 2026 earnings at $3.53 EPS, Q4 2026 earnings at $3.53 EPS and FY2026 earnings at $13.66 EPS.

Several other research firms also recently commented on SRPT. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. UBS Group upped their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price for the company. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Evercore ISI lowered their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Trading Up 1.4 %

Shares of Sarepta Therapeutics stock opened at $126.27 on Thursday. The firm has a market cap of $12.06 billion, a price-to-earnings ratio of 101.02 and a beta of 0.77. Sarepta Therapeutics has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The business has a fifty day simple moving average of $122.11 and a 200-day simple moving average of $131.33. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Sarepta Therapeutics in the 3rd quarter worth about $79,425,000. Janus Henderson Group PLC increased its stake in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares during the last quarter. Soros Fund Management LLC purchased a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $25,800,000. Finally, Blair William & Co. IL lifted its position in shares of Sarepta Therapeutics by 303.7% during the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after buying an additional 131,112 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.